[Form 4] Cytosorbents Corp. Insider Trading Activity

Rhea-AI Filing Summary

Michael G. Bator, a director of Cytosorbents Corporation (CTSO), reported a transaction dated 08/08/2025 in which he disposed of 151,273 shares of common stock and was granted stock options to purchase 44,000 shares at an exercise price of $1. The 151,273 shares reported include 3,300 RSUs (granted 03/15/2018), 6,000 RSUs (02/24/2017), 60,000 RSUs (06/07/2016) that vest upon a Change of Control, and 81,973 shares owned outright by the reporting person. The options were granted under the CytoSorbents 2014 Long-Term Incentive Plan and vest in four equal quarterly installments over one year, subject to continued service, with an expiration indicated as 08/08/2035.

Positive

• Director received a material equity-based grant: 44,000 stock options at a $1 exercise price, aligning incentives with shareholders if the director remains in service.
• Vesting clarity: Options vest in four equal quarterly installments over one year, and RSU grants and their grant dates are explicitly disclosed.

Negative

• Large disposition reported: Disposal of 151,273 common shares could meaningfully change insider ownership percentages relative to prior holdings.
• No sale price disclosed: The Form does not state the proceeds or price for the disposed shares, limiting assessment of economic impact.

Insights

Financial Analyst

TL;DR: Director sold 151,273 shares and received 44,000 options; lack of sale price limits assessment of market impact.

The filing shows a substantial disposition of 151,273 common shares and a contemporaneous grant of options to purchase 44,000 shares at a $1 exercise price. The option grant vests in four equal quarterly installments over one year, providing service-based retention. Because the Form does not disclose a sale price for the disposed shares, the economic impact and potential market signaling are unclear. The reported holdings include 81,973 shares owned outright, with additional RSUs contingent on a Change of Control.

Corporate Governance Expert

TL;DR: Grant structure ties compensation to continued service; disposed shares include change-of-control RSUs, which remain contingent.

The report identifies RSUs that vest only upon a Change of Control (3,300; 6,000; 60,000) and an ownership stake of 81,973 shares, aggregated in the disclosed 151,273 disposed shares. The 44,000 stock options were issued under the company’s 2014 Long-Term Incentive Plan and vest quarterly over one year, which is a short-term service contingent schedule designed to retain the director for the next year. The filing provides explicit grant and RSU grant dates but does not disclose sale proceeds or the reason for the disposition.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BATOR MICHAEL G.

(Last) (First) (Middle)

C/O CYTOSORBENTS CORPORATION

305 COLLEGE ROAD EAST

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cytosorbents Corp [ CTSO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								151,273(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1	08/08/2025		A		44,000		(2)	08/08/2035	Common Stock	44,000	$0	44,000	D

Explanation of Responses:

1. Includes (a) the following restricted stock units ("RSUs") which will vest upon a "Change of Control" of the Company, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (i) 3,300 RSUs granted on March 15, 2018, (ii) 6,000 RSUs granted on February 24, 2017, and (iii) 60,000 RSUs granted on June 7, 2016, and (b) 81,973 shares of Common Stock owned by the Reporting Person.

2. The stock options were granted pursuant to the Plan. The shares underlying the stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

	/s/ Peter J. Mariani attorney-in-fact Michael G. Bator	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Michael G. Bator report on Form 4 for CTSO?

The filing reports a disposition of 151,273 common shares and a grant of stock options to purchase 44,000 shares at $1, with transactions dated 08/08/2025.

Which RSUs are included in the 151,273 shares reported?

The 151,273 shares include RSUs of 3,300 (granted 03/15/2018), 6,000 (granted 02/24/2017), and 60,000 (granted 06/07/2016) that vest upon a Change of Control, plus 81,973 shares owned outright.

What are the terms and vesting schedule of the option grant?

The options were granted under the 2014 Long-Term Incentive Plan with an exercise price of $1; they vest in four equal quarterly installments over one year, subject to continued service, and show an expiration date of 08/08/2035.

What is the reporting person’s relationship to CTSO?

Michael G. Bator is reported as a Director of Cytosorbents Corporation and the Form was filed by one reporting person.

Does the Form disclose the sale price or proceeds from the disposition?

No. The filing does not disclose a sale price or the proceeds for the 151,273 shares disposed.